Search

Dmitri D Kharkevitch

from Houston, TX
Age ~66

Dmitri Kharkevitch Phones & Addresses

  • 37 Lana Ln, Houston, TX 77027 (713) 960-0431
  • 7900 Cambridge St, Houston, TX 77054 (281) 797-1623
  • San Diego, CA
  • Lawrenceville, NJ
  • 37 Lana Ln, Houston, TX 77027 (713) 447-1440

Work

Company: Bristol-myers squibb - Princeton, NJ Jan 2013 Position: Global medical lead, yervoy

Education

School / High School: Rice University Jesse H. Jones Graduate School of Management Sep 2007 Specialities: Certificate in Education

Skills

Pharmaceutical Industry • Clinical Trials • Clinical Research • Clinical Development • Oncology • Life Sciences • Biotechnology • Cancer • Healthcare • Medical Affairs • Medicine • Strategic Planning • Medical Devices • Microsoft Office • Project Management • Customer Service • Microsoft Excel • Gmp • Pharmaceutical Sales • Cross Functional Team Leadership • Quality Assurance • Product Development

Languages

English

Industries

Pharmaceuticals

Resumes

Resumes

Dmitri Kharkevitch Photo 1

Chief Medical Officer

View page
Location:
San Diego, CA
Industry:
Pharmaceuticals
Work:
Curematch
Chief Medical Officer

Huya Bioscience International Mar 2015 - Nov 2017
Vice President, Clinical Development

Bristol-Myers Squibb 2013 - 2013
Global Medical Director
Education:
Ni Pirogov Medical School, Moscow, Russia
Doctor of Medicine, Doctorates, Medicine
Skills:
Pharmaceutical Industry
Clinical Trials
Clinical Research
Clinical Development
Oncology
Life Sciences
Biotechnology
Cancer
Healthcare
Medical Affairs
Medicine
Strategic Planning
Medical Devices
Microsoft Office
Project Management
Customer Service
Microsoft Excel
Gmp
Pharmaceutical Sales
Cross Functional Team Leadership
Quality Assurance
Product Development
Languages:
English
Dmitri Kharkevitch Photo 2

Dmitri Kharkevitch Lawrenceville, NJ

View page
Work:
BRISTOL-MYERS SQUIBB
Princeton, NJ
Jan 2013 to Jun 2013
Global Medical Lead, Yervoy

VICAL, INC

2010 to 2013
Executive Director

VICAL, INC
San Diego, CA
2008 to 2013

VICAL, INC

2008 to 2010
Executive Director

INTROGEN THERAPEUTICS, INC
Houston, TX
2006 to 2008
Senior Director, Clinical Affairs

ANTIGENICS, INC
Lexington, MA
2003 to 2005
Clinical Liaison, Medical Affairs

ROCHE PHARMACEUTICALS
Nutley, NJ
1999 to 2002
Clinical Medical Liaison, Oncology, Medical Affairs

Subsidiary of Rush-Presbyterian - St. Luke's Medical Center
Chicago, IL
1997 to 1999

UNIVERSITY OF TEXAS

1993 to 1997
Instructor in Surgical Oncology and Assistant Immunologist

UNIVERSITY OF TEXAS

1992 to 1997
Laboratory Manager, Melanoma Vaccine Laboratory

UNIVERSITY OF TEXAS
Texas, MD
1990 to 1997
MD ANDERSON CANCER CENTER - Houston

UNIVERSITY OF TEXAS

1991 to 1993
Research Associate

UNIVERSITY OF TEXAS

1990 to 1991
Postdoctoral Fellow

N.N. BLOKHIN CANCER CENTER

1979 to 1990
Associate Professor, Clinical Immunology/Oncology, Department of Clinical Radioimmunology

INTROGEN THERAPEUTICS, INC
London
Jul 2008 to Present
Advexin clinical trials in head and neck cancer

Education:
Rice University Jesse H. Jones Graduate School of Management
Sep 2007
Certificate in Education

N.N. Blokhin Cancer Center
1991
Oncology

N.N. Blokhin Cancer Center
1983
Ph.D. in Oncology

N.I. Pirogov Medical School
1979
M.D.

Publications

Us Patents

Synergistic Anti-Tumor Efficacy Using Alloantigen Combination Immunotherapy

View page
US Patent:
20130273078, Oct 17, 2013
Filed:
Mar 14, 2013
Appl. No.:
13/830543
Inventors:
Vical Incorporated - , US
John Doukas - Encinitas CA, US
Dmitri Kharkevitch - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 39/395
A61K 31/7088
US Classification:
4241731
Abstract:
The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, β2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject. The MHC antigen may be HLA-B7.

Synergistic Anti-Tumor Efficacy Using Alloantigen Combination Immunotherapy

View page
US Patent:
20130280265, Oct 24, 2013
Filed:
Mar 14, 2013
Appl. No.:
13/830462
Inventors:
Vical Incorporated - , US
John Doukas - Encinitas CA, US
Dmitri Kharkevitch - San Diego CA, US
International Classification:
A61K 39/395
A61K 39/00
US Classification:
4241421, 4241731, 4241441
Abstract:
The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, β2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject. The MHC antigen may be HLA-B7.

Synergistic Anti-Tumor Efficacy Using Alloantigen Combination Immunotherapy

View page
US Patent:
20130071403, Mar 21, 2013
Filed:
Sep 18, 2012
Appl. No.:
13/622210
Inventors:
Vical Incorporated - San Diego CA, US
John Doukas - Encinitas CA, US
Dmitri Kharkevitch - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 39/395
A61P 35/04
A61P 35/00
US Classification:
4241421, 4241721
Abstract:
The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, β2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject. The MHC antigen may be HLA-B7.
Dmitri D Kharkevitch from Houston, TX, age ~66 Get Report